Skip to content

myoinositol and sexual function

Evaluation of the effect of myoinositol on the sexual function of patients with polycystic ovary syndrome treated with cyproterone compound

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160524028038N17
Enrollment
60
Registered
2023-07-03
Start date
2023-07-08
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: inofolic powder (2 grams myoinositol + 400 micrograms folic acid
daily,12 weeks) along with cyproterone compound tablet (21 days per monthly cycle, 3 months). Intervention 2: Control group: Cyproterone compound tablet (21 days per monthly cycle, 3 months).

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: age 18 to 40 years Confirmation of polycystic ovary syndrome based on the Rotterdam criteria Iranian Absence of severe mental conditions since six months before the research Not suffering from severe depression and anxiety according to the depression and anxiety questionnaire No current use of psychiatric medications No language or cognitive problems preventing the patient from completing the questionnaire No smoking No current use of drugs affecting sexual function Failure to previously diagnose an organic cause for sexual dysfunction by an experienced physician Currently taking cyproterone compound tablets as prescribed by the gynecologist

Exclusion criteria

Exclusion criteria: Patients who do not want to cooperate. Pregnancy during study

Design outcomes

Primary

MeasureTime frame
Sexual function. Timepoint: Before the intervention and three after the intervention. Method of measurement: sexual function questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvin-Alsadat Eslamnik

Yasouj University of Medical Sciences

f.bazarganipour@gmail.com+98 74 3333 7251

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026